Association Between VEGF Splice Isoforms and Progression-free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab
Overview
Authors
Affiliations
Purpose: Bevacizumab improves survival for patients with metastatic colorectal cancer with chemotherapy, but no proven predictive markers exist. The VEGF-A splice form, VEGF(165)b, anti-angiogenic in animal models, binds bevacizumab. We tested the hypothesis that prolonged progression-free survival (PFS) would occur only in patients with low relative VEGF(165)b levels treated with bevacizumab.
Experimental Design: Blinded tumor samples from the phase III trial of FOLFOX4 ± bevacizumab were assessed for VEGF(165)b and VEGF(total) by immunohistochemistry and scored relative to normal tissue. A predictive index (PI) was derived from the ratio of VEGF(165)b:VEGF(total) for 44 samples from patients treated with FOLFOX + bevacizumab (arm A) and 53 samples from patients treated with FOLFOX4 (arm B), and PFS, and overall survival (OS) analyzed on the basis of PI relative to median ratio.
Results: Unadjusted analysis of PFS showed significantly better outcome for individuals with VEGF(165)b:VEGF(total) ratio scores below median treated with FOLFOX4 + bevacizumab compared with FOLFOX4 alone (median, 8.0 vs. 5.2 months; P < 0.02), but no effect of bevacizumab on PFS in patients with VEGF(165)b:VEGF(total) ratio >median (5.9 vs. 6.3 months). These findings held after adjustment for other clinical and demographic features. OS was increased in arm A (median, 13.6 months) compared with arm B (10.6 months) in the low VEGF(165)b group, but this did not reach statistical significance. There was no difference in the high VEGF(165)b:VEGF(total) group between FOLFOX + bevacizumab (10.8 months) and FOLFOX alone (11.3 months).
Conclusion: Low VEGF(165)b:VEGF(total) ratio may be a predictive marker for bevacizumab in metastatic colorectal cancer, and individuals with high relative levels may not benefit.
Quan B, Li Z, Yang H, Li S, Yan X, Wang Y Heliyon. 2023; 9(8):e18706.
PMID: 37554848 PMC: 10405001. DOI: 10.1016/j.heliyon.2023.e18706.
Nishio M, Atagi S, Goto K, Hosomi Y, Seto T, Hida T Transl Lung Cancer Res. 2023; 12(6):1167-1184.
PMID: 37425411 PMC: 10326775. DOI: 10.21037/tlcr-22-632.
A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma.
Montemagno C, Durivault J, Gastaldi C, Dufies M, Vial V, He X Mol Oncol. 2023; 17(7):1379-1401.
PMID: 36810959 PMC: 10323879. DOI: 10.1002/1878-0261.13401.
Talotta R Microorganisms. 2022; 10(12).
PMID: 36557705 PMC: 9784975. DOI: 10.3390/microorganisms10122452.
Zhang H, Han B, Han X, Zhu Y, Liu H, Wang Z Front Genet. 2021; 12:736423.
PMID: 34630526 PMC: 8497829. DOI: 10.3389/fgene.2021.736423.